Welcome to our dedicated page for Painreform news (Ticker: PRFX), a resource for investors and traders seeking the latest updates and insights on Painreform stock.
PainReform Ltd. (Nasdaq: PRFX) generates news across two main areas: specialty pharmaceutical development for post-surgical pain and ophthalmology, and AI-driven solar and energy analytics through its DeepSolar platform. Company updates often highlight progress in extended-release drug-delivery technologies and in advanced digital tools for managing solar assets.
On the pharmaceutical side, news items cover developments in PRF-110, PainReform’s oil-based ropivacaine formulation for localized post-operative analgesia, and the OcuRing™-K program acquired through its majority investment in LayerBio. Releases describe preclinical and clinical milestones for OcuRing-K, including Phase I safety data in cataract surgery patients and R&D assessments showing that the sustained-release matrix can incorporate multiple drug entities such as corticosteroids and NSAIDs. These updates provide insight into how the company is pursuing dropless, sustained-release approaches to post-cataract pain and inflammation management.
In parallel, DeepSolar-related news focuses on AI-based solar analytics and energy optimization. Coverage includes the development of DeepSolar Predict, an AI forecasting module for photovoltaic systems advanced within the NVIDIA Connect program, the launch of Smart TDD for solar technical due diligence, and progress on an automated reporting engine that consolidates operational data into tailored performance reports. PainReform has also reported on pilot and commercial engagements for DeepSolar, such as a 92MW project with Econergy Renewable Energy.
Investors and observers can use this news feed to follow regulatory and clinical steps for PainReform’s pharmaceutical candidates, as well as product launches, technology collaborations, and commercial milestones in its DeepSolar business. Regular updates provide context on how the company advances its dual focus on non-opiate pain management and renewable-energy analytics.
FAQ
What is the current stock price of Painreform (PRFX)?
What is the market cap of Painreform (PRFX)?
